New drug JBZ-001 enters first human trial for Hard-to-Treat cancers

NCT ID NCT06801002

Recruiting now Disease control Sponsor: Jabez Bioscience, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to check safety, find the best dose, and see if the drug shows any signs of shrinking tumors. Because this is the first time JBZ-001 is being tested in humans, the focus is on safety and dosing, not yet on proving it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JBZ-001 (a drug that blocks a protein called DHODH, which cancer cells need to grow)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong: This is a very early, first-in-human trial with only 25 participants, so the drug may not be effective or could have unexpected side effects. Success in this small study does not guarantee broader benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma lymphoma mantle cell lymphoma neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.